HIGHLIGHTS
• Zelda to work with one of Australia’s leading medical research institutes, the Telethon Kids Institute
• Expands pre-clinical research programme from breast cancer to now include paediatric brain cancers
• Rigorous series of experiments to generate high quality data pack
• Follows on from recently announced positive results from Zelda’s pre-clinical breast cancer research being conducted in Spain
• Data expected during 2017
"Zelda intends on sourcing the cannabinoid research material via a supply agreement with AusCann Group Holdings Ltd. AusCann has a partnership with the world’s largest medical cannabis cultivator and processor - Canadian group Canopy Growth Corporation. Subject to AusCann securing the appropriate import permits, and Canopy securing an export permit, this material will be sourced from Canada and supplied to the Telethon Kids Institute for the approved research purposes. These research activities fall within the recently passed Australian Narcotics Drug Amendment Act and re-scheduling of cannabis from Schedule 9 (prohibited substance) to Schedule 8 (controlled drug) under the Poisons Standard."
ZLD Price at posting:
3.1¢ Sentiment: Buy Disclosure: Held
